CG Oncology GAAP EPS of -$0.71, revenue of $1.08B

* CG Oncology press release [https://seekingalpha.com/pr/20507681-cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-updates] (CGON [https://seekingalpha.com/symbol/CGON]): Q1 GAAP EPS of -$0.71.
* Revenue of $1.08M.
* Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2026 were $1.1 billion, compared with $742.2 million as of December 31, 2025. The March 31, 2026, cash includes net proceeds of approximately $391.4 million from a total of 6,941,407 shares sold through the Company’s at-the-market (ATM) facility in Q1 based on reverse inquiries from existing and new, high-quality funds.

MORE ON CG ONCOLOGY

* CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) [https://seekingalpha.com/article/4888459-cg-oncology-passing-a-red-line-for-what-i-would-call-a-reasonable-valuation]
* Seeking Alpha’s Quant Rating on CG Oncology [https://seekingalpha.com/symbol/CGON/ratings/quant-ratings]
* Historical earnings data for CG Oncology [https://seekingalpha.com/symbol/CGON/earnings]
* Financial information for CG Oncology [https://seekingalpha.com/symbol/CGON/income-statement]